Acasti Pharma Inc ACST.V :
* ACASTI PHARMA PROVIDES BUSINESS UPDATE FOR THE FIRST QUARTER OF FISCAL 2020
* ACASTI PHARMA INC - ON TRACK TO REPORT TOPLINE RESULTS FOR TRILOGY 1 IN DECEMBER 2019 AND TRILOGY 2 IN JANUARY 2020
* ACASTI PHARMA INC - FULLY FUNDED BEYOND COMPLETION OF PHASE 3 STUDIES
* ACASTI PHARMA INC - AT JUNE 30, 2019, ACASTI HAD $25.4 MILLION OF CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES
* ACASTI PHARMA INC - QTRLY LOSS PER SHARE $0.15
* ACASTI PHARMA - WILL NEED TO RAISE ADDITIONAL CAPITAL IN FUTURE TO COMPLETE FUNDING OF PREPARATION & FILING NDA, AND US COMMERCIAL LAUNCH ACTIVITIES
* ACASTI - THERE IS MATERIAL UNCERTAINTY ABOUT CO'S ABILITY TO CONTINUE AS GOING CONCERN & TO REALIZE ASSETS % DISCHARGE LIABILITIES IN NORMAL COURSE